AF3485, a human mPGES-1 inhibitor, exhibits anti-tumor activity both in vitro and in vivo. It achieves this by reducing PGE2 production, inhibiting EGFR signaling, and decreasing the expression of VEGF and FGF-2, which suppresses tumor-associated angiogenesis. When subchronically administered to mice with human A431 xenograft tumors, AF3485 effectively curtails tumor growth.